Skip to content

Observation of the therapeutic effect of stellate ganglion block combined with sphenopalatine ganglion block on allergic rhinitis

Observation of the therapeutic effect of stellate ganglion block combined with sphenopalatine ganglion block on allergic rhinitis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500095832
Enrollment
Unknown
Registered
2025-01-14
Start date
2025-01-20
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic rhinitis

Interventions

Stellar ganglion block group:Under ultrasound guidance, puncture to the stellate ganglion position, inject 1% lidocaine 4 m, alternate left and right block, twice a day, and the successful block is ma
Butterfly palate ganglion block group:Sphenopalatine ganglion block group: puncture to the pterygopalatine fossa under ultrasound guidance, inject 0.25% lidocaine + Diprosone 1mg + normal saline mixtu
Stellar ganglion block combined with sphenopalatine ganglion block group:The stellate ganglion combined with sphenopalatine ganglion block group, the treatment method is the same as above, and one wee

Sponsors

Jiangsu Subei People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Age>18 years old; 2) All meet the diagnostic criteria for allergic rhinitis; 3) No other allergic rhinitis treatments were used during the treatment period.

Exclusion criteria

Exclusion criteria: 1) Exclude patients with severe nasal bleeding, nasopharyngeal tumors, developmental abnormalities, and other organic lesions of organs; 2) Individuals with COPD, bronchiectasis, tuberculosis, and respiratory infections; 3) Individuals with dependence on anesthesia or psychotropic drugs, history of surgery, and failure to follow medical advice for treatment and examination.

Design outcomes

Primary

MeasureTime frame
VAS;

Secondary

MeasureTime frame
Clinical efficacy;

Countries

China

Contacts

Public ContactGuan Jingjing

Subei People's Hospital

744415478@qq.com+86 180 5106 2752

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026